Kymera Therapeutics, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.kymeratx.com

Moat Score

Market Cap $1.85B
PE -8
Debt -
Cash $120.26M
EV -
FCF -$207.34M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$223.86M
EBIT	-$261.64M
ROE	-27%
ROA	-27%
FCF	-$207.34M
Equity	$835.62M
Growth Stability	1
PE	-8.26
PB	2.21
P/FCF	-8.91
P/S	39.26
Price/Cash	0.07
Net Margins	-476%
Gross Margins	0%
Op. Margins	-556%
Sales Growth YoY	-85%
Sales Growth QoQ	98%
Sales CAGR	14%
FCF CAGR	-0%
Equity CAGR	25%
Earnings Growth YoY	392%

Earnings Growth QoQ	13%
Sales CAGR 5Y	14%
FCF CAGR 5Y	-0%
Equity CAGR 5Y	26%
Earnings CAGR 3Y	14%
Sales CAGR 3Y	14%
Equity CAGR 3Y	29%
Market Cap	$1.85B
Revenue	$47.07M
Assets	$978.04M
Cash	$120.26M
Shares Outstanding	64.89M
Moat Score	1%
Working Capital	442.5M
Current Ratio	7.53
Gross Profit	$0.00
Shares Growth 3y	9%
Equity Growth QoQ	-6%
Equity Growth YoY	112%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

SEC Filings

Direct access to Kymera Therapeutics, Inc. (KYMR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Kymera Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Kymera Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Kymera Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Kymera Therapeutics, Inc..

Years

Calculation mode

= -$2.1B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$207M	-$207M	-$207M	-$207M	-$206M	-$206M	-$206M	-$206M	-$205M	-$205M	-$205M	-$2B
DCF		-$188M	-$171M	-$155M	-$141M	-$128M	-$116M	-$105M	-$96M	-$87M	-$79M	-$790M
Value	-$2.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-1K%	-161%	-138%	-331%	-187%	-476%	-476%
ROA	-	-10%	-17%	-27%	-29%	-27%	-27%
ROE	-	-19%	-22%	-32%	-37%	-27%	-27%

Bad Net Margins (-475.57%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	1K%	114%	-36%	68%	-40%	14%
Earnings YoY growth	-	32%	83%	54%	-5%	52%	-
Equity YoY growth	-	-482%	62%	7%	-19%	112%	26%
FCF YoY growth	-	355%	-265%	19%	-12%	51%	-0%